Baclofen for binge eating: An open-label trial

Allegra I. Broft, Alexia Spanos, Rebecca L. Corwin, Laurel Mayer, Joanna Steinglass, Michael J. Devlin, Evelyn Attia, B. Timothy Walsh

Research output: Contribution to journalArticle

50 Scopus citations

Abstract

Objective: Baclofen is a GABA-B agonist that may be useful in the treatment of substance use disorders, and also reduces 'binge-like' eating in rodents. We hypothesized that baclofen might be effective in reducing binge eating episodes in binge eating disorder (BED) and bulimia nervosa (BN). Method: Seven women with BED (n = 4) or BN (n = 3) took baclofen (60 mg/day) for 10 weeks. Results: Six out of seven patients completed the full 10-week trial. Five out of seven participants (3 BED; 2 BN) demonstrated 50% or greater reduction of frequency of binge eating from beginning to end of the study. Three out of seven participants (2 BED; 1 BN) were free of binge eating at study end. Four out of seven participants elected to continue baclofen at study end. Baclofen was well tolerated by the participants. Conclusion: In this open-label trial, baclofen was associated with decreased binge eating frequency in patients with BED and BN.

Original languageEnglish (US)
Pages (from-to)687-691
Number of pages5
JournalInternational Journal of Eating Disorders
Volume40
Issue number8
DOIs
StatePublished - Dec 1 2007

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Baclofen for binge eating: An open-label trial'. Together they form a unique fingerprint.

  • Cite this

    Broft, A. I., Spanos, A., Corwin, R. L., Mayer, L., Steinglass, J., Devlin, M. J., Attia, E., & Walsh, B. T. (2007). Baclofen for binge eating: An open-label trial. International Journal of Eating Disorders, 40(8), 687-691. https://doi.org/10.1002/eat.20434